William Blair analyst Matt Larew has maintained their bullish stance on WST stock, giving a Buy rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Matt Larew has given his Buy rating due to a combination of factors including West Pharmaceutical Services’ strong third-quarter performance, which exceeded both the firm’s and market expectations. The company’s revenue reached $804.6 million, surpassing the estimated $789.3 million, driven by a 5.0% organic growth. Proprietary products and high-value product (HVP) components significantly contributed to this growth, with HVP components making up 48% of total sales.
Additionally, the company has raised its guidance for 2025, projecting increased sales and earnings per share, which indicates confidence in its future performance. The guidance now forecasts reported sales between $3.060 billion and $3.070 billion, with organic growth expected to be between 3.75% and 4%. This positive outlook, coupled with the easing of inventory destocking and growth in key product areas like GLP-1s, supports the Buy rating.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $318.00 price target.